Modernizing preclinical safety assessments, Certara software delivers an intuitive, integrated suite through ToxStudio to help pharmaceutical and biotech organizations rapidly evaluate compound toxicity and predict critical outcomes like drug-induced liver injury and QT risks. By leveraging advanced artificial intelligence-powered quantitative structure-activity relationship modeling and Bayesian predictive tools, the platform identifies safety hazards even before compound synthesis occurs. This proactive approach empowers research teams to prioritize safer chemical leads, answer complex "what-if" questions, and effortlessly generate regulatory-ready reports, significantly streamlining safety workflows and reducing costly late-stage failures across the entire development pipeline.

Join for free to read